TECH OFFERS

In precision manufacturing, the ability to maintain optimum efficiency and accuracy is of critical importance. This AI Platform addresses these challenges by utilizing proprietary self-improving AI models for Automatic Defect Classification (ADC). This innovative solution incorporates AI Equipment Automation and Root Cause Mapping and provides a comprehensive system that significantly enhances production efficiency. The system seamlessly integrates Equipment Risk Analysis into existing alert mechanisms thus reducing downtime and increasing yield. At its core, it operates as a robust AI platform, featuring a user-centric interface for Machine Learning Operations (MLOps). This promotes recipe-free inspection while maintaining compatibility with a broad range of third-party software. The technology is modular and provides smooth productization of multiple AI solutions thereby increasing the effectiveness of defect inspection and analysis, assisting in equipment error recovery, and providing insights for process optimization. The technology offers an attractive solution for manufacturers across different industries interested in increasing their production efficiency and improving product quality. The technology features AI at its core to provide multiple AI tools in a modularized form for different inspection, maintenance, and process control related tasks common in precision manufacturing industry: High precision recipe-free AI based visual defect inspection and classification. Root cause mapping for indicating errors in upstream process. Non-intrusive equipment run status monitoring and error assist using learned behaviour from UI messages and operator interventions. Equipment health monitoring and logging. Equipment insight generation for process optimization and recipe refinement. Checklist based assistance and tracking for preventive maintenance and assists. Predictive maintenance capability. Ideal collaboration partners span semiconductor manufacturers, pharmaceutical firms and other precision manufacturing industries, hardware manufacturers for the production and upgrades of the vision systems, and research institutions focusing on AI. This technology has applications  in the manufacturing operations for the following industries: MedTech Pharmaceuticals Semiconductor Electronics Automotive Precision Engineering Aerospace With the projected growth and with production schedules becoming increasingly demanding, the ability to harness the power of artificial intelligence for predictive maintenance, process optimization, and quality control is a game-changer. These tools not only enhance the overall productivity but also enable companies to maintain a competitive edge in an ever-evolving landscape.  This technology is particularly attractive to these markets due to its ability to drastically reduce scrap rates and improve OEE (Overall Equipment Efficiency), thereby leading to significant cost savings. The growing trend of automation and AI adoption in manufacturing presents a substantial market opportunity for this technology.  The unique value proposition of the AI platform lies in its increased precision, flexibility, scalability, and seamless integration into existing manufacturing ecosystems: The solution does not require a complete overhaul of the existing setup. The solution includes a full toolset for autonomous operations - standalone AI assisted inspection, preventive maintenance, modules for reducing machine downtimes and manual assists (OEE). All actions taken are fully tracked for unique insights, root cause analysis, assisted recipe creation and process optimization. Flexible and capable of integrating techniques, like hyperspectral imaging, for insights into material properties among others. Modular and capable of adapting to various operational needs spanning different industries. Cost effective and easy integration to existing manufacturing lines. Manufacturing, Assembly, Automation & Robotics

Egg white is a well-known super-food as an absolute protein with a complete essential amino acid profile, easily digestible, and no cholesterol. While salted egg yolks are a common ingredient in many traditional Asian dishes, the egg white is discarded as it has limited applications due to its high salt content. This technology valorizes the salted egg white waste from the production of salted egg yolks into a tofu-like form that has many culinary applications. This is done using a patent-pending technique that is developed for desalination and reformation of egg white protein. The process uses a thermal membrane technique to desalinate the egg white and then aggregate the egg white protein from the salted egg white sidestream. The current production volume of this product is 50 kg/day. The egg white product is 100% natural with no additives. It comes in the form of a semi-gel “tofu”. Per 100 g of tofu, it contains 54 kcal, and 307 mg of sodium with a 12.5% protein content wet weight basis. Its texture is firmer and more chewy than regular egg white. - Suitable to be incorporated into culinary applications e.g. tofu basil stir fry, grilled tofu, salad/wrap topping - Suitable for elderly, patients, fitness enthusiasts, flexitarians, health-conscious, people seeking convenience At present, the global market size of egg white protein is valued at roughly 20 billion USD. However, there is still a large amount of egg white being discarded each year, especially in the salted egg yolk industry. The estimated value of upcycling this waste stream is estimated to be valued at 170 M baht (4.7M USD) within 3 years. This product is a healthy, tasty food with natural ingredients and no food additives that is also easy and convenient to eat. Its protein content is greater than regular egg white due to the concentration by the thermal membrane technology. This product is also easy to incorporate into culinary applications with a pleasant taste. High Protein, Egg White, Tofu, Protein Recovery, Zero-Waste Foods, Ingredients, Processes, Sustainability, Food Security

Biomarkers are biomolecules and/or physical characteristics found in the body that give a clear picture of a person’s health and fitness. Currently, the golden standard of biomarker testing is through blood tests. However, this method is invasive as it involves drawing blood with a needle. Additionally, blood tests are neither real-time nor continuous which means there is significant delay between testing and receiving results. Such problems can be solved through this invention as this method involves sensing biomarkers within sweat through a skin patch, eschewing the need for needles. Furthermore, the biomarker data can be instantly transmitted to a smartphone application which allows users to continuously monitor their data in a convenient manner.  This technology would be relevant in numerous industries such as sports fitness, beauty, and medical diagnostics; thus, attracting sizable demand for it where there is an unmet need for convenient, accurate and real time detection of accurate biomarkers. The technology consists of the following main parts:  The underlying substrate of the sweat sensor is made from advanced Ultra High Molecular Weight Polyethylene (UHMWPE) membrane which can adhere to skin without needing any adhesive. The membrane itself has the Janus property which allows biomarkers of interest to enter the sensor on the skin-side while blocking interferents such as water droplets from entering on the opposite side. The sensors use selective biomolecule detection using specially molecularly imprinted polymers (MIP) that binds to a target biomarker to generate a response signal.  The transducer part converts the biomolecular signal into an electrical signal to be processed and transmitted into the smartphone application. The smartphone app interprets and shows the data to the user with the goal of delivering insights on the user’s health and fitness.  There are several potential industries where this technology can be customised:  Sports Performance Monitoring: This technology can detect changes in lactate levels in athletes. Currently, athletes regularly use invasive blood pricks to obtain insights and improve on their lactate threshold (maximum lactate concentration in blood in which the athletes will experience fatigue). With this technology, athletes can not only bypass the invasive blood pricking but also continuously monitor their lactate levels during training instead of relying on multiple point-in-time measurements that might give an incomplete picture of their fitness levels  Beauty: Another biomarker this technology can detect is changes in cortisol, a stress hormone that negatively impacts skin health. Beauty-conscious users can apply a skin patch to detect their stress levels and perhaps implement the optimal skin care routine. Medical diagnostics: Current biomarker detection methods for medical diagnostics still rely on blood testing, which is invasive and relies on delayed point-in-time measurements. Sweat sensing using this skin-adhering sensor can give continuous non-stop insights to medical providers to optimise care based on the physiological state of the patient. The global wearable health sensors market size accounted for USD 2.9 Billion in 2022 and is estimated to achieve a market size of USD 14.1 Billion by 2032, growing at a CAGR of 17.4% from 2023 to 2032. (Source: Acumen Research and Consulting). With more people becoming health-conscious, there is an escalating demand for technologies that can assist in monitoring and enhancing their health. Wearable health sensors cater to this need by offering real-time data on a range of health parameters. In recent years, significant research has been targeted toward the development of wearable sensing devices for monitoring biomarker levels in nonobtrusively accessible biofluids such as tears, urine, saliva, and sweat. Sweat could be an ideal candidate for prolonged, semicontinuous, and non-obtrusive health monitoring because sweat is a continuously accessible biofluid containing physiologically and metabolically rich information such as biomarkers.  State of the art for biomarker detection is through using blood tests. This technology is an improvement over blood tests as it is non-invasive and increases user convenience. It has advantages in delivering real-time and continuous data to users which creates a clearer picture of the user’s health and fitness, allowing for rapid action to be taken if necessary. This contrasts with blood tests which usually require a few days between blood taking and results publishing.  This technology is an improvement as it can measure relevant biomarkers providing a more insightful view of the user’s health and with modular sensing (meaning products based on this technology can be easily modified to detect different biomarkers or even detect multiple biomarkers at once). The technology serves as a platform for customisation with multiple potential use cases in numerous industries.  skin sensor, sweat sensor, non-invasive sensor, biomarker sensor, real time data, continious monitoring, wearable, skin wearable, skin patch, wearable sensor, sweat, biomarker, platform technology Electronics, Sensors & Instrumentation, Healthcare, Diagnostics, Medical Devices

Amidst the imposition of compulsory climate reporting by regulatory bodies in some nations including Singapore, a powerful carbon accounting software solution has been devised. This aims to aid and fortify companies in their readiness to adhere to this necessity and embark on their sustainability journey. The software suite consists of the following solutions: GHG Emissions Management: Efficiently manage and reduce your organisation's greenhouse gas (GHG) emissions. ESG Reporting: Streamline and simplify your Environmental, Social, and Governance (ESG) reporting process. Environmental Compliance: Propel your organisation towards comprehensive ISO 14001 environmental stewardship. 24/7 Electricity Emissions Traceability: Navigate your decarbonisation journey with real-time, precise and transparent electricity emissions tracking. GHG Emissions Management At the heart of the software suite is the GHG Emissions Management solution. An all-in-one GHG emissions management software, to streamline calculating, tracking, and reporting your organisation's greenhouse gas (GHG) emissions for Scope 1, 2, and 3 activities. Accurate & Instant Emissions Calculations Transparent Target Setting & Progress Tracking Actionable Insights for Emissions Reduction Seamless Integration & Automation Data Validation & Stakeholder Engagement Offset Your Unavoidable Emissions Simplified Reporting & Compliance ESG Reporting Navigating the complex world of ESG reporting is now easier than ever with a powerful, user-friendly solution designed to save your organisation time, reduce stress, and optimise your reporting process across multiple international frameworks. Easily share disclosure questions to individuals across your company, manage their response and get knowledge from your disclosures by turning them from a compliance burden to valuable business insight. ESG Framework Templates Hub – GRI, TCFD, CDP, SASB and more ESG Data Consolidation Portal   Customised Data Insights Suite Environmental Compliance The solution incorporates features to support you when complying with ISO14001. Store all documents in one place, identify nonconformities, and create effective action plans. Audit Management and Reporting Data Health Check and Warnings Documentation Repository Data Verification and Tracking Automated Data Collection Target Setting and Tracking Electricity Emissions Traceability A latest feature is Electricity Emissions Traceability: Get real-time, precise and transparent electricity emissions tracking telling the user the intensity of the electricity from their grid on an hourly basis.   The suite of solutions are aimed at organisations taking proactive steps to measure and report their environmental and social impacts. GHG Emissions Management: Aimed at those organisations already calculating their carbon footprint looking for a more efficient solution or consultants providing carbon accounting as a service. ESG Reporting: Is useful for organisations already struggling with the compliance burden of disclosing to a different frameworks looking for ways to increase the efficiency of the process. Environmental Compliance: A solution perfect for any organisation who is ISO14001 accredited. 24/7 Electricity Emissions Traceability: A must have for those trailblazers wanting to go that step further and set an example for more accurate scope 2 reporting to encourage carbon free energy production locally.  This software solution provides sustainability consultants and partners allowing for a well-structured solution implemented quickly for their clients. This suite of software solutions is unique in combining a powerful carbon accounting tool with ESG reporting framework support, ISO14001 compliance functionality and real time scope 2 emissions reporting. Limited software company provides this suite of solutions designed to help you collect, calculate, measure, report and disclose your ESG data.     Infocomm, Big Data, Data Analytics, Data Mining & Data Visualisation, Green ICT, Sustainability, Low Carbon Economy

In 2022, about 83 million patients suffer from insulin-dependent diabetes worldwide. From 2021 to 2045, this number is projected to increase by 46% globally. Despite the availability of approved insulin therapy as the standard of care, up to a quarter of these patients still suffer from poor blood glucose control, which can lead to a fatal drop in blood glucose levels. The team has developed a cell-encapsulating macro-device as an implant to reduce the risk of fatal drop in blood sugar of insulin-dependent diabetic patients. This patent-pending, injection-free cellular implant can effectively manage insulin-dependent diabetes by enabling enhanced survival of therapeutic insulin-secreting cells. After a simple under-skin insertion of the macro-device, the cells in this implant can sense the blood glucose level of a diabetic patient and secrete insulin to continuously provide injection-free, precise glucose control. The device also protects the insulin secreting therapeutic cells by encapsulating them in a hydrogel to shield them from immune attacks and alleviate the patient from the need for immunosuppression. This technology could offer a safer alternative treatment for these insulin-dependent patients who experience poor blood glucose control with conventional insulin therapy. This platform technology includes two main components: a protective hydrogel membrane and living therapeutic cells. These cells are encapsulated within the hydrogel, which has controllable pores. These pores are large enough for nutrients and therapeutic agents to pass through, allowing the cells to survive and function normally. Furthermore, the pore size is small enough to block the entry of immune cells and harmful molecules, protecting the therapeutic cells from the patient's immune system. This protection eliminates the need for lifelong use of immunosuppressants, easing the burden on the patient. Once implanted inside the patient, the therapeutic cells inside the device can sense the biological environment and secrete their therapeutic agents, typically insulin in the case of diabetes, as required. The proprietary device design also improves oxygen access for the therapeutic cells by arranging them in donut-shaped microtissues, providing more surface area for oxygen intake compared to their natural spheroidal shape. These microtissues are then organized into arrays to prevent aggregation, enhancing survival of the therapeutic cells and potentially prolonging treatment duration without the need for additional agents or accessories. The technology development is currently focusing on treatment for insulin-dependent diabetes. In addition to this indication, it could serve as a platform technology for the treatment of other hormone-deficiency diseases by encapsulating different types of therapeutic cells to secrete missing hormones of interest. The applicable indications include, but are not limited to, hemophilia A and thyroid disorder. With 83 million patients worldwide suffering from insulin-dependent diabetes in 2022, there is an urgent unmet need for a safer alternative treatment for patients unresponsive to insulin therapy. The proposed cellular therapy has the potential to fulfil this need, and there is no similar treatment already approved and available in the market. Targeting the young insulin-dependent patient population (Type 1 Diabetes) experiencing poor blood glucose control and able to afford the treatment, it is estimated that the service obtainable market in the United States could achieve an annual revenue of approximately 70 million USD. A similar estimation values the Chinese market at 37 million USD annually.  The  macro-device implant is designed to provide continuous and precise blood glucose control without requiring manual intervention and injection. The proprietary hydrogel design provides protection from immune rejection as alleviating the patient from the burden of lifelong immunosuppressant usage. The device design also potentially improves the survival of encapsulated cells, promising a sustainable and prolonged efficacious duration without overburdening the patient with additional accessories. diabetes, type 1 diabetes, injection free insulin delivery, insulin, insulin delivery, cell therapy, therapeutics, stem cells, hydrogel, implant, implant device Healthcare, Medical Devices, Pharmaceuticals & Therapeutics

Histopathology is a cornerstone of modern medicine, providing crucial information that enables doctors to formulate optimal treatment strategies before, during, and after surgeries. However, current methods for obtaining histological images grapple with a compromise between speed and accuracy and suffer from organ-dependent inconsistencies. Addressing these challenges, our technology was developed as a versatile solution to cater to a wide array of clinical scenarios. It sets a new benchmark for medical standards with its rapid, precise, and label-free on-the-spot imaging capability. Computation High-throughput Autofluorescence Microscopy by Pattern Illumination is a one-of-a-kind patented solution n that can detect and provide instant information about cancer status before, during, and after surgeries. This technology lets surgeons place fresh tissue samples taken directly from the patient into the microscope and receive high-resolution and virtually stained histological images in just three minutes. The primary adopters of this technology are expected to be healthcare organizations, hospitals, and research institutions, or any entity involved in histopathology, cancer diagnosis, and surgery. This technology fills a crucial void in the market by providing swift, high-resolution, label-free imaging of thick tissue samples, an achievement previously unattainable. Consequently, this technology not only accelerates the diagnostic process but also enhances its precision, revolutionizing the field of histopathology This is an innovative solution designed to revolutionize histological imaging. It consists of several key components that contribute to its functionality: Ultraviolet Light Source: The microscope uses UV light to excite the surface of the specimen, which generates autofluorescence from the biomolecules. This autofluorescence is then captured to produce a high-resolution grayscale image. Low-magnification Objective Lens: This component provides a large field of view and is insensitive to the surface roughness of the sample. Despite its low magnification, it contributes to the high imaging speed of the technology. Pattern Illumination: This technique has been incorporated to overcome the limitations of the low-magnification lens. It helps to mathematically retrieve high-frequency signals and reconstruct high-resolution images by capturing more details and contours. Deep-learning Algorithm: This deep learning algorithm is developed to virtually stain the grayscale images with over 90% accuracy, transforming them into virtually stained H&E images. This aids in the interpretation of the images by pathologists, facilitating an easier and swift adaptation of the technology. The technology holds immense potential across various sectors, predominantly in healthcare and medical research. It can be utilized during biopsy sessions preceding surgeries, providing doctors with a rapid means to verify sample sufficiency. This capability can minimize the need for repeated biopsies, thereby improving patient comfort and experience. Furthermore, it aids in preserving the integrity of the tissue sample, facilitating subsequent consumptive testing. In the operating room, this technology can serve as an intraoperative imaging tool, potentially replacing frozen sections. This enables more rapid and precise intraoperative margin analysis during various cancer resection surgeries. With its capacity for swift and accurate imaging of freshly-excised thick tissue, our technology  is anticipated to play an instrumental role in promoting conservative surgeries. Such procedures aim to preserve more normal tissues during tumor removal, enhancing patient physiological function and life expectancy without compromising treatment efficacy. Lastly, the device can function as a tool for the digitization of tissue samples post-surgery. Hospitals often retain tissue samples for up to 10 years as a reference record. However, physical storage demands significant space and resources to maintain tissue conditions. The  ability to digitize these tissues provides a more accessible and convenient resource for research institutes and doctors to conduct further studies, thereby optimizing storage and potentially expediting medical research. The market size for the technology is substantial, considering it serves the healthcare and medical research sectors, both of which are substantial and growing markets. The global histopathology services market was valued at around USD 22.68 billion in 2020 and projected to grow at a CAGR of 6.5% from 2021 to 2028, reaching approximately USD 37 billion by 2028. The market for medical imaging equipment, which the CHAMP Microscope™ would also fall under, was projected to reach USD 43.3 billion by 2027. These figures suggest a substantial potential market for the technology. This technology stands as a significant improvement over the current clinical gold standard in histopathological imaging. The traditional methods, including Formalin-fixed Paraffin-Embedded (FFPE) and frozen section analysis, are either time-consuming or lack precision.  The Unique Value Proposition (UVP) lies in the ability to significantly reduce the time required for histopathological imaging while maintaining high accuracy this technology   Speed and Accuracy:  Offer a high-resolution, label-free imaging solution that can generate high-quality images in just three minutes, a significant improvement over current histopathology methods. Thick Tissue Staining : Technology can be used with both slides and freshly-excised thick tissue, eliminating the need for labour-intensive tissue processing and chemical staining. Versatility: The technology is applicable across a wide range of clinical scenarios, making it a versatile tool for various healthcare and research institutions. Deep Learning Model : The integration of a deep learning algorithm  for virtual staining enhances the technology's appeal by minimizing the learning curve for pathologists, making the transition to this new technology smoother. Cost and Resource Efficiency: By enabling on-the-spot imaging and reducing the need for repeated biopsies and surgeries, the technology can lead to significant cost and resource savings for healthcare providers. Patient Outcomes: By facilitating real-time decision-making during surgeries, the technology can improve patient outcomes. In sum, the technology offers a faster, more accurate, and more versatile solution for histopathological imaging, significantly enhancing clinical workflow efficiency and potentially leading to better patient outcomes. This combination of speed, accuracy, and convenience sets apart from the current clinical gold standards. Healthcare, Diagnostics, Medical Devices, Telehealth, Medical Software & Imaging

Patients who have stroke, brain injuries, cerebral palsy, arthritis or suffer from other neurological disorders often experience motor impairments; patients with delayed or lack of rehabilitation suffer from more severe physical sequelae, such as, spasticity and muscle atrophy, which decreases their level of independence It has been reported by World Health Organisation, that the need for rehabilitation continues to grow worldwide, especially in low- and middle income countries. The demand for rehabilitation services already exceeds availability, leaving a large unmet need. Longer life expectancies and increasing survival rates for those with severe disability, coupled with the rising prevalence of chronic diseases means that globally there will be an increase in the health burden associated with limitations in functioning. For both the patients and therapists, there is a need for efficient models of rehabilitation care are needed. This invention is of a robotic manipulator that can assist or be programmed to move or mobilize patients’ limbs or joints repetitively during rehabilitation or to perform daily tasks, for e.g., of gripping a cup, bowl or utensil, in a safe, reliable and effective manner. The device can be used in a clinical and/or at-home setting. This invention is of a hybrid robotic manipulator that consists of both soft and rigid materials, with a portable base, modular design and sensing elements integrated for more functions. The technology was developed to aid physiotherapists in doing repetitive rehabilitation motions for bed-ridden patients. This innovative solution for patients allows them to regain their upper limb motor functions and improve their quality of life. The technology can be used as an upper limb rehabilitation system that is portable, comfortable, lightweight, and user-friendly. With its versatility and flexibility, this system can be deployed in places where assistance for rehabilitation of the patients is needed, such as hospitals, rehabilitation centres and elder-care centres to do simple repetitive rehabilitation motions for the patients, such as shoulder flexion/extension, shoulder abduction/adduction, elbow flexion/extension, etc.  The global rehabilitation robots market was valued at USD 226.0 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 17.3% from 2022 to 2030 (Source: Grand View Research). The growth can be attributed to the rising per capita healthcare spending and rapid adoption of technologically advanced equipment in the healthcare sector. The rising prevalence of stroke and the rapidly growing population of older adults are some of the key driving factors responsible for the growth. Technological advancements are also playing a major role in supporting industry growth. Furthermore, increasing disorders such as cumulative trauma disorder, repetitive strain injury, and occupational overuse syndromes further impact the market positively. A large population with musculoskeletal disorders, spinal cord injury, and others tend to move to hospitals for rehabilitation services, thereby boosting the growth of the segment. In addition, surging awareness regarding technologically advanced systems, along with a rise in the number of FDA approvals on medical exoskeletons, is anticipated to drive the segmental growth. Couple this, with the acute shortage of qualified physiotherapists to address the expected increase in patient demand, indicates a strong market potential for assistive rehabilitation robotic technologies such as this invention. This hybrid robotic arm ensures better safety during human-robotic interactions, and demonstrated higher force, versatility and portability compared to existing robotic arms. The key feature of this invention provides: Better safety: The robotic arm was created with both rigid and soft materials. The core of the hybrid robotic arm was made of aluminium as the supporting structure, and the outer layer was made of fabric air pockets as the protective material. Compared to traditional rigid robotic arms, the hybrid robotic arm ensures better safety during human-robotic interactions, as well as higher portability which increases user convenience. Reconfigurable modular robotic arm: All modules of the hybrid robotic arm are exchangeable, which allows the robotic arm to exhibit different arm length and various configurations such as beam-joint-beam and beam-beam-joint, according to the application requirements. Integrated sensing elements for easier control: Machine Learning based sensing elements are integrated to the system to allow a playback learning capability in which the physiotherapists can teach the system to perform a rehabilitation motion along a desired path of motion, and to provide data for the physiotherapists to track and analyze rehabilitation progress of the patients Physiotheraphy, Soft Robotics, Robotics, stroke rehabilitation, rehabilitation, robots, rehabilitation robots, modular, robotic arm, robotic manipulator Healthcare, Medical Devices

This technology portfolio covers wearable sensing and haptics for Virtual Reality (VR). The wearable sensors can provide gesture-based control in VR without the need for cameras, providing interactive control for VR for lower end headset. The sensor use electronic textiles and a patented sensing scheme that requires no additional electronics except a microcontroller. They present ultralow latency (<1ms), can distinguish between wearer and non-wearer and have exceptional noise rejection. The haptics technology allows for simulation of resistance and micro sensations on the fingers and palm. This is crucial for applications like surgical training, as surgeons routinely rely on their sense of touch in real world scenarios. The jamming technology uses textile-based actuators and pneumatics, making it the lightest wearable technology for haptics. Sensing: Textile-based wearable sensors woven into gloves. Custom microcontroller mounted on the glove. Proprietary signal conditioning and processing algorithm. Haptics: 3D-printec micro haptics actuators, as well as 3D printed+ fabric-based jamming actuators.Pnuematics pressure source, valves and control box. VR-based training is the main target for the haptics. The tech owner has signed LOIs with studios with downstream medical clients. The patented sensing methods allows for ultralow latency (<1ms) sensing with almost no hysteresis, which is unique in case of wearable soft sensors. This makes them ideal for use in applications like gaming and other wearable input devices, where other soft sensor leave a lot to be desired for a good user experience.   Sensing: Gaming and VR interaction- without the need for extra cameras: the wearable sensing provides a cheaper alternative to additional headset cameras. Haptics: Medical training professionals- haptics is crucial for applications like surgical training where dexterity needs to be trained. Current applications of VR can only train procedures. XR based training is becoming popular as it saves up to 80% cost compared to traditional methods and improves retention by up to 4x. The market for XR hardware is already a S$2.6B market and growing rapidly. The market is project to grow 40-50% YOY over the next 5 years. This is greatly being aided by addition of application layers such as OpenXR that allow for cross-compatibility between hardware such as the devices we are building. The sensor can distinguish between wearer and non-wearer, has exceptional noise resistance, and the system has extremely low power consumption owing to the sensing method used. The jamming haptics technology uses fabric-based jamming which is the lightest in-class for wearables. This makes it ideal for applications where dexterity is requited- such as VR surgical training. The micro-haptics uses 3D printed designs that supply higher force output at lower pressures due to their patented multi-layer design. Infocomm, Internet of Things

Systemic drug administration has conventionally been prescribed to alleviate persistent local inflammation which is prevalent in chronic diseases. However, this approach is associated with drug-induced toxicity, particularly when the dosage exceeds what is necessitated from the pathological conditions of the diseased tissues. This technology developed is a novel drug delivery technology that is activated to enable the release of appropriate drug payload according to the patient’s condition on the level of disease severity. The drug delivery system is a modular hybrid hydrogel carrier encapsulating the required anti-inflammatory drug which is triggered to release upon exposure to elevated markers of inflammation such as increased protease activity which is commonly upregulated in inflammatory diseases.   The technology has been validated for its material, safety, and toxicity studies on ex vivo exudates of clinical samples, in vivo wound model, and arthritis diseased mouse model. The primary targeted indication is Rheumatoid arthritis based on its significant disease unmet need and market size. It aims to become a platform technology as an effective therapy against chronic inflammatory diseases such as inflammation bowel diseases, chronic wounds and topical application. The convenience of the technology offers significant societal benefits, particularly for ageing populations where the incidence of pain and inflammation arising from diseases becomes prevalent with age while potentially eliminating adverse side effects from traditional delivery of drug administration.  The technology owner is seeking for collaborations with clinicians, biopharma, biotech companies looking for novel drug delivery systems. The platform technology is based on a hydrogel system with a proprietary modular design for which drug component and inflammation-sensing component can be selected and tailored based on the profile of an inflammatory disease of interest. Key features of this platform drug delivery technology are: Modular in design Immuno-compatible Versatile for both injectable into joints and topical application on wound This drug delivery system is formulated into an injectable pain-relieving gel for arthritic patients. With a single injection into the joints of arthritis patients, the therapeutic drug within the hydrogel formulation will be released at a dosage matching the intensity and frequency of inflammation flares to achieve prolonged control of inflammation and pain. This analgesic product solution can help arthritic patients avoid frequent steroid injections while maintaining pain-free joints with minimal risk of adverse side effects. The stage of the technolgy can be applied with Steroidal and Non-steroidal anti-inflammatory drugs (NSAIDs) currently. This drug delivery platform offers a versatile platform for biomarker dependant drug dose release and delivery at appropriate inflammation site via either an injectable or topical application to effectively manage long-term inflammation seen in chronic conditions. The technology can be applied to create precision therapeutics in injectable or topical formulation to treat chronic inflammation conditions such as arthritis, skin inflammatory diseases, Inflammatory Bowel Diseases (IBD), chronic wounds and Chronic Obstructive Pulmonary Diseases (COPD) which can be potentially expanded to other areas including eye, skin and dental as a pain control for inflammation and the possibility of encapsulating proteins and peptides. The estimated Total Available Market (TAM), which is the global rheumatology therapeutics market, was USD 48.4 billion in 2020 with an expected growth to USD $64.4B by 2028, expanding at a CAGR of 3.1% during this forecast period. The Serviceable Available Market (SAM), estimated base on corticosteroid market for management of arthritic flare as the primary indication, accounts for 25% of joint-pain injection market which will be worth USD $9.2 billion by 2030. The technology is in PCT national regional phase entry for several markets including USA, China, EU, Japan, Korea, and Australia.  Key features of this precision medicine: Effective management of inflammatory condition Minimize adverse side effects Minimize frequency of drug administration Precision Medicine, Drug Delivery, Anti-inflammation, Chronic disease, Hydrogel, Arthritis Healthcare, Medical Devices, Pharmaceuticals & Therapeutics